Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers

enthalten in: Annals of oncology | 18 August 2022

von Jahn, A. | Rump, A. | Widmann, T. | +75